KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zimmer Biomet Holdings (ZBH) EBIT Margin (2016 - 2026)

Zimmer Biomet Holdings has reported EBIT Margin over the past 18 years, most recently at 17.88% for Q1 2026.

  • For Q1 2026, EBIT Margin rose 257.0% year-over-year to 17.88%; the TTM value through Mar 2026 reached 14.02%, down 302.0%, while the annual FY2025 figure was 13.34%, 340.0% down from the prior year.
  • EBIT Margin for Q1 2026 was 17.88% at Zimmer Biomet Holdings, up from 6.89% in the prior quarter.
  • Over five years, EBIT Margin peaked at 19.23% in Q4 2024 and troughed at 1.55% in Q4 2022.
  • A 5-year average of 14.62% and a median of 15.32% in 2024 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: surged 1981bps in 2023 and later crashed -1234bps in 2025.
  • Year by year, EBIT Margin stood at 1.55% in 2022, then skyrocketed by 1277bps to 18.26% in 2023, then grew by 5bps to 19.23% in 2024, then tumbled by -64bps to 6.89% in 2025, then surged by 160bps to 17.88% in 2026.
  • Business Quant data shows EBIT Margin for ZBH at 17.88% in Q1 2026, 6.89% in Q4 2025, and 17.55% in Q3 2025.